CYP2J2

Cytochrome P450 2J2 · P51589 · CYP2J2 on Sugi Atlas →

42,601 patent compounds predicted against CYP2J2, 34,053 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL48803	0.75	13/20
Ebastine (SCHEMBL18467)	0.65	5/20
Carebastine (SCHEMBL18538)	0.55	5/20
Fexofenadine (SCHEMBL121920)	0.74	4/20
Fexofenadine (SCHEMBL4900)	0.80	3/20
Fexofenadine (SCHEMBL4901)	0.80	3/20
Fexofenadine (SCHEMBL40914)	0.79	3/20
Fexofenadine (SCHEMBL40915)	0.79	3/20
Fexofenadine (SCHEMBL48729)	0.77	3/20
SCHEMBL55533	0.60	3/20
SCHEMBL375079	0.41	3/20
SCHEMBL561423	0.40	3/20
Terfenadine (SCHEMBL5152)	1.00	2/20
Perphenazine (SCHEMBL42125)	1.00	2/20
R-Terfenadine (SCHEMBL155924)	1.00	2/20
Terfenadine (SCHEMBL137824)	0.94	2/20
SCHEMBL196765	0.73	2/20
Fexofenadine (SCHEMBL361347)	0.59	2/20
1,3,5-Trimethoxybenzene (SCHEMBL28493)	0.55	2/20
Fexofenadine (SCHEMBL298333)	0.53	2/20

Clinical trials — most relevant to CYP2J2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparative Effects of Azithromycin, Telithromycin and Levofloxacin on Drug Metabolizing Enzymes	PHASE4	COMPLETED
The Effect of Montelukast in Patients With Chronic Cough and Bronchial Hyperreactivity	PHASE4	COMPLETED
Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing	PHASE4	COMPLETED
The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans	PHASE4	COMPLETED
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer	PHASE2	COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma	PHASE2	NOT_YET_RECRUITING
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy	PHASE2	COMPLETED
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis	PHASE2	ACTIVE_NOT_RECRUITING
3 Month PHI PAD PoM Study	PHASE2	COMPLETED
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia	PHASE2	COMPLETED
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer	PHASE1	COMPLETED
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies	PHASE1	UNKNOWN
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Pharmacokinetics of BF2.649 in Renal Impairment	PHASE1	COMPLETED
A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients	PHASE1	COMPLETED
A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants	PHASE1	COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects	PHASE1	NOT_YET_RECRUITING
Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults	EARLY_PHASE1	NOT_YET_RECRUITING
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk	nan	COMPLETED
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors	nan	COMPLETED
Pharmacogenomic Profiling of Pediatric Patients	nan	COMPLETED
Cytochrome P450 2D6 (CYP 450 2D6) Genotype and Flecainide Efficacy	nan	UNKNOWN
Eicosanoids in Human Heart Failure	nan	UNKNOWN
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis	nan	COMPLETED
Clopidogrel Preventive Effect Based on CYP2C19 Genotype in Ischemic Stroke	nan	COMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP2J2 binder may also engage these)

Protein	Name	Similarity
O54749	—	1.000	O54749 →
O54750	—	1.000	O54750 →
P51590	—	0.999	P51590 →
Q9QXF7	—	0.998	Q9QXF7 →
P11714	—	0.996	P11714 →
P52786	—	0.996	P52786 →
Q9QUJ1	—	0.996	Q9QUJ1 →
P51581	—	0.996	P51581 →
P11711	—	0.996	P11711 →
Q6GUQ4	—	0.995	Q6GUQ4 →
Q91W64	—	0.995	Q91W64 →
P12938	—	0.995	P12938 →
P56593	—	0.994	P56593 →
CYP2E1	Cytochrome P450 2E1	0.994	landscape →
O18963	—	0.994	O18963 →
P79383	—	0.994	P79383 →
P11510	—	0.994	P11510 →
P19225	—	0.994	P19225 →
P24455	—	0.992	P24455 →
Q9QYG5	—	0.992	Q9QYG5 →
P08682	—	0.992	P08682 →
Q05421	—	0.992	Q05421 →
Q29510	—	0.992	Q29510 →
P24456	—	0.991	P24456 →
P10633	—	0.991	P10633 →
Q9MZY0	—	0.991	Q9MZY0 →
P56657	—	0.990	P56657 →
E9Q5K4	—	0.990	E9Q5K4 →
P33272	—	0.990	P33272 →
P20814	—	0.990	P20814 →